DE69833545D1 - In der zellmembran verankertes antikoagulant-fusionsprotein - Google Patents

In der zellmembran verankertes antikoagulant-fusionsprotein

Info

Publication number: DE69833545D1
Authority: DE; Germany
Prior art keywords: anticoagulant; cell; proteins; rejection; fusion protein
Prior art date: 1997-03-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

DE69833545T

Other languages

English (en)

Other versions

DE69833545T2 (de

Inventor

Kristian Riesbeck

Anthony Dorling

Andrew John Timothy George

Robert Jan Lechler

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Ip2ipo Innovations Ltd

Original Assignee

Imperial College Innovations Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-03-26

Filing date

1998-03-26

Publication date

2006-04-27

1997-03-26 Priority claimed from GBGB9706327.5A external-priority patent/GB9706327D0/en

1997-09-23 Priority claimed from GBGB9720248.5A external-priority patent/GB9720248D0/en

1998-03-26 Application filed by Imperial College Innovations Ltd filed Critical Imperial College Innovations Ltd

2006-04-27 Application granted granted Critical

2006-04-27 Publication of DE69833545D1 publication Critical patent/DE69833545D1/de

2006-12-14 Publication of DE69833545T2 publication Critical patent/DE69833545T2/de

2018-03-27 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000003146 anticoagulant agent Substances 0.000 title abstract 2
229940127219 anticoagulant drug Drugs 0.000 title abstract 2
210000000170 cell membrane Anatomy 0.000 title abstract 2
108020001507 fusion proteins Proteins 0.000 title 1
210000004027 cell Anatomy 0.000 abstract 3
239000002506 anticoagulant protein Substances 0.000 abstract 2
210000000056 organ Anatomy 0.000 abstract 2
108090000623 proteins and genes Proteins 0.000 abstract 2
102000004169 proteins and genes Human genes 0.000 abstract 2
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 abstract 1
102000007625 Hirudins Human genes 0.000 abstract 1
108010007267 Hirudins Proteins 0.000 abstract 1
102100030951 Tissue factor pathway inhibitor Human genes 0.000 abstract 1
101710181904 Venom factor Proteins 0.000 abstract 1
239000004019 antithrombin Substances 0.000 abstract 1
230000020411 cell activation Effects 0.000 abstract 1
230000003111 delayed effect Effects 0.000 abstract 1
229960002897 heparin Drugs 0.000 abstract 1
229920000669 heparin Polymers 0.000 abstract 1
WQPDUTSPKFMPDP-OUMQNGNKSA-N hirudin Chemical compound C([C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC(OS(O)(=O)=O)=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H]1NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]2CSSC[C@@H](C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N[C@H](C(NCC(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)N2)=O)CSSC1)C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]1NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)CSSC1)C(C)C)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 WQPDUTSPKFMPDP-OUMQNGNKSA-N 0.000 abstract 1
229940006607 hirudin Drugs 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
108010013555 lipoprotein-associated coagulation inhibitor Proteins 0.000 abstract 1
230000017570 negative regulation of blood coagulation Effects 0.000 abstract 1
230000001105 regulatory effect Effects 0.000 abstract 1
210000004739 secretory vesicle Anatomy 0.000 abstract 1
239000003998 snake venom Substances 0.000 abstract 1
230000008685 targeting Effects 0.000 abstract 1
108010065972 tick anticoagulant peptide Proteins 0.000 abstract 1
210000001519 tissue Anatomy 0.000 abstract 1
238000002054 transplantation Methods 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1
238000002689 xenotransplantation Methods 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70514—CD4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/7056—Lectin superfamily, e.g. CD23, CD72
- C07K14/70564—Selectins, e.g. CD62
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70571—Receptors; Cell surface antigens; Cell surface determinants for neuromediators, e.g. serotonin receptor, dopamine receptor
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
- C07K14/811—Serine protease (E.C. 3.4.21) inhibitors
- C07K14/8114—Kunitz type inhibitors
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/81—Protease inhibitors
- C07K14/815—Protease inhibitors from leeches, e.g. hirudin, eglin
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6402—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals
- C12N9/6418—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from non-mammals from snakes
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/07—Animals genetically altered by homologous recombination
- A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/103—Ovine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/108—Swine
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/01—Animal expressing industrially exogenous proteins
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/02—Animal zootechnically ameliorated
- A01K2267/025—Animal producing cells or organs for transplantation
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
- C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/033—Fusion polypeptide containing a localisation/targetting motif containing a motif for targeting to the internal surface of the plasma membrane, e.g. containing a myristoylation motif
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Biochemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Biophysics (AREA)
Medicinal Chemistry (AREA)
Wood Science & Technology (AREA)
Immunology (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Plant Pathology (AREA)
Physics & Mathematics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Neurology (AREA)
Tropical Medicine & Parasitology (AREA)
Environmental Sciences (AREA)
Transplantation (AREA)
Diabetes (AREA)
Hematology (AREA)
Animal Husbandry (AREA)
Biodiversity & Conservation Biology (AREA)

DE69833545T 1997-03-26 1998-03-26 In der zellmembran verankertes antikoagulant-fusionsprotein Expired - Lifetime DE69833545T2 (de)

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
GBGB9706327.5A GB9706327D0 (en)	1997-03-26	1997-03-26	Coagulation inhibition
GB9706327		1997-03-26
GBGB9720248.5A GB9720248D0 (en)	1997-09-23	1997-09-23	Coagulation inhibition
GB9720248		1997-09-23
PCT/GB1998/000850 WO1998042850A1 (en)	1997-03-26	1998-03-26	Anticoagulant fusion protein anchored to cell membrane

Publications (2)

Publication Number	Publication Date
DE69833545D1 true DE69833545D1 (de)	2006-04-27
DE69833545T2 DE69833545T2 (de)	2006-12-14

Family

ID=26311272

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DE69833545T Expired - Lifetime DE69833545T2 (de)	1997-03-26	1998-03-26	In der zellmembran verankertes antikoagulant-fusionsprotein

Country Status (12)

Country	Link
US (3)	US6423316B1 (de)
EP (2)	EP1000161B1 (de)
JP (3)	JP4243355B2 (de)
KR (1)	KR100561055B1 (de)
CN (1)	CN1192109C (de)
AT (1)	ATE318316T1 (de)
AU (1)	AU733681B2 (de)
CA (1)	CA2285702C (de)
DE (1)	DE69833545T2 (de)
ES (2)	ES2513043T3 (de)
NZ (1)	NZ500007A (de)
WO (1)	WO1998042850A1 (de)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6395338B1 (en) *	1999-03-19	2002-05-28	Rhodia Chimie	Process and device for coating a support using a crosslinkable silicone composition
ES2513043T3 (es) *	1997-03-26	2014-10-24	Imperial Innovations Limited	Proteína de fusión anticoagulante anclada a membrana de la célula
EP1010762A1 (de) *	1998-12-02	2000-06-21	Aventis Behring Gesellschaft mit beschränkter Haftung	DNS-Konstrukte von Blutgerinnungsfaktoren und P-Selektin
EP1026250A1 (de) *	1998-12-02	2000-08-09	Aventis Behring GmbH	DNs-Konstructs von Blutgerinnungsfaktoren und P-Selektin
SE523817C2 (sv)	1999-02-05	2004-05-18	Corline Systems Ab	Användning av ett koagulationsförebyggande ämne i samband med transplantation av insulinproducerande celler
AU3703200A (en) *	1999-02-22	2000-09-14	Instrumentation Laboratory	Recombinant protein c activator and uses therefor
JP2001211882A (ja) *	2000-01-31	2001-08-07	Shiyuuji Miyagawa	移植関連タンパク質をコードするコドン改変型遺伝子
DE10033195A1 (de) *	2000-07-07	2002-03-21	Aventis Pharma Gmbh	Bifunktionale Fusionsproteine aus Hirudin und TAP
DE60232071D1 (de)	2001-06-11	2009-06-04	Applied Nanosystems Bv	Verfahren zur bindung von acma-typ protein anker fusionen an mikroorganismen zellwandmaterialien
EP1651050B1 (de)	2003-07-21	2012-08-22	Lifecell Corporation	Zellfreie gewebsmatrize aus galactose-alpha-1,3-galactose-freiem gewebe
CN104721883A (zh)	2004-03-17	2015-06-24	雷维维科公司	来源于缺乏任何功能性α1,3半乳糖基转移酶表达的动物的组织产品
CA2958259C (en)	2004-10-22	2020-06-30	Revivicor, Inc.	Ungulates with genetically modified immune systems
US20060148080A1 (en) *	2004-12-30	2006-07-06	Paul Diamond	Methods for supporting and producing human cells and tissues in non-human mammal hosts
US9216212B2 (en) *	2005-08-05	2015-12-22	University Of Massachusetts	Virus-like particles as vaccines for paramyxovirus
US7951384B2 (en) *	2005-08-05	2011-05-31	University Of Massachusetts	Virus-like particles as vaccines for paramyxovirus
CA2909775A1 (en) *	2005-08-09	2007-03-29	Revivicor, Inc.	Transgenic ungulates expressing ctla4-ig and uses thereof
KR101112713B1 (ko) *	2008-06-13	2012-02-24	인제대학교 산학협력단	인간 면역반응 조절인자(ｈＤＡＦ)와 인간 조직혈액응고 억제인자(ＴＦＰＩ) 기능부위와 ＣＤ4의 세포표면 부착부위와의 융합유전자(ｈＴＦＰＩ/ｈＣＤ4)를 조합 발현하는 단일 벡터 및 그 제조방법
AU2010282239A1 (en) *	2009-08-14	2012-03-08	Revivicor, Inc.	Multi-transgenic pigs for diabetes treatment
GB0915519D0 (en) *	2009-09-04	2009-10-07	King S College London	Ntithrombotic compounds
US9420770B2 (en)	2009-12-01	2016-08-23	Indiana University Research & Technology Corporation	Methods of modulating thrombocytopenia and modified transgenic pigs
EP2534257B1 (de)	2010-02-12	2017-09-27	Oncomed Pharmaceuticals, Inc.	Verfahren zur identifikation und isolierung von zellen zur expression von polypeptiden
CN102939098B (zh)	2010-03-01	2016-08-03	拜耳医药保健有限公司	针对组织因子途径抑制剂(tfpi)的优化的单克隆抗体
NZ759163A (en) *	2011-02-14	2023-03-31	Revivicor Inc	Genetically modified pigs for xenotransplantation of vascularized xenografts and derivatives thereof
US20140115728A1 (en)	2012-10-24	2014-04-24	A. Joseph Tector	Double knockout (gt/cmah-ko) pigs, organs and tissues
WO2015007880A1 (en)	2013-07-19	2015-01-22	Novo Nordisk A/S	Antibodies recognizing the n-terminal part of tissue factor pathway inhibitor capable of eliciting pro-coagulant activity
US10307510B2 (en)	2013-11-04	2019-06-04	Lifecell Corporation	Methods of removing alpha-galactose
DE102014103706B4 (de) *	2014-03-18	2018-05-30	Pratap Banerjee	Vorrichtung zur Simulation gynäkologischer Operationen
KR101939198B1 (ko) *	2017-06-27	2019-01-16	고려대학교 산학협력단	돼지 및 인간 조직혈액응고 억제인자 융합 이뮤노글로불린
GB201804092D0 (en) *	2018-03-14	2018-04-25	Imperial Innovations Ltd	Methods and compositions
WO2021061872A1 (en) *	2019-09-24	2021-04-01	The Regents Of The University Of California	Novel receptors having a heterologous stop transfer sequence for ligand-dependent transcriptional regulation
CN112083172B (zh) *	2020-09-17	2024-01-26	鄂尔多斯市中心医院（内蒙古自治区超声影像研究所）	一种从蜱cDNA文库中筛选具有抗凝血活性的蛋白质的方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5109113A (en) *	1986-05-02	1992-04-28	Genentech, Inc.	Membrane anchor fusion polypeptides
ES2060561T3 (es)	1989-10-12	1996-08-01	Imutran Ltd	Material biologico modificado.
ES2267093T3 (es) *	1990-11-29	2007-03-01	Cropdesign N.V.	Control de la proliferacion y crecimiento de celulas en vegetales.
US5223408A (en) *	1991-07-11	1993-06-29	Genentech, Inc.	Method for making variant secreted proteins with altered properties
ZA941414B (en) *	1993-03-02	1994-09-28	Novo Nordisk A G	Non-glycosylated TFPI analogues
US5891645A (en) *	1994-06-01	1999-04-06	Alexion Pharmaceuticals, Inc.	Porcine E-selectin
US5589359A (en) *	1994-08-05	1996-12-31	Chiron Corporation	Chimeric proteins
AU707762B2 (en) *	1994-08-05	1999-07-22	Novartis Vaccines And Diagnostics, Inc.	Production of tissue factor pathway inhibitor
GB9517779D0 (en)	1995-08-31	1995-11-01	Roslin Inst Edinburgh	Biological manipulation
ES2513043T3 (es)	1997-03-26	2014-10-24	Imperial Innovations Limited	Proteína de fusión anticoagulante anclada a membrana de la célula

1998
- 1998-03-26 ES ES05077712.7T patent/ES2513043T3/es not_active Expired - Lifetime
- 1998-03-26 AU AU67383/98A patent/AU733681B2/en not_active Ceased
- 1998-03-26 EP EP98912600A patent/EP1000161B1/de not_active Expired - Lifetime
- 1998-03-26 WO PCT/GB1998/000850 patent/WO1998042850A1/en active IP Right Grant
- 1998-03-26 US US09/402,515 patent/US6423316B1/en not_active Expired - Lifetime
- 1998-03-26 AT AT98912600T patent/ATE318316T1/de not_active IP Right Cessation
- 1998-03-26 CN CNB988054531A patent/CN1192109C/zh not_active Expired - Fee Related
- 1998-03-26 NZ NZ500007A patent/NZ500007A/en unknown
- 1998-03-26 JP JP54522098A patent/JP4243355B2/ja not_active Expired - Lifetime
- 1998-03-26 CA CA2285702A patent/CA2285702C/en not_active Expired - Lifetime
- 1998-03-26 ES ES98912600T patent/ES2259206T3/es not_active Expired - Lifetime
- 1998-03-26 DE DE69833545T patent/DE69833545T2/de not_active Expired - Lifetime
- 1998-03-26 KR KR1019997008736A patent/KR100561055B1/ko not_active IP Right Cessation
- 1998-03-26 EP EP05077712.7A patent/EP1676920B1/de not_active Expired - Lifetime
2002
- 2002-03-18 US US10/101,523 patent/US20050118160A1/en not_active Abandoned
2008
- 2008-01-16 JP JP2008007332A patent/JP2008109939A/ja not_active Withdrawn
2009
- 2009-11-26 JP JP2009269347A patent/JP2010279348A/ja active Pending
2011
- 2011-03-17 US US13/050,120 patent/US9376684B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1265148A (zh)	2000-08-30
WO1998042850A1 (en)	1998-10-01
DE69833545T2 (de)	2006-12-14
AU6738398A (en)	1998-10-20
US20120017288A1 (en)	2012-01-19
EP1676920A3 (de)	2007-07-25
JP4243355B2 (ja)	2009-03-25
JP2008109939A (ja)	2008-05-15
AU733681B2 (en)	2001-05-24
CN1192109C (zh)	2005-03-09
EP1676920A2 (de)	2006-07-05
CA2285702C (en)	2016-06-28
JP2001523094A (ja)	2001-11-20
JP2010279348A (ja)	2010-12-16
ES2513043T3 (es)	2014-10-24
KR100561055B1 (ko)	2006-03-16
US6423316B1 (en)	2002-07-23
CA2285702A1 (en)	1998-10-01
US9376684B2 (en)	2016-06-28
NZ500007A (en)	2001-08-31
US20050118160A1 (en)	2005-06-02
EP1000161A1 (de)	2000-05-17
ES2259206T3 (es)	2006-09-16
KR20010005668A (ko)	2001-01-15
ATE318316T1 (de)	2006-03-15
EP1000161B1 (de)	2006-02-22
EP1676920B1 (de)	2014-07-09

Publication	Publication Date	Title
ATE318316T1 (de)	2006-03-15	In der zellmembran verankertes antikoagulant- fusionsprotein
Carrell et al.	1985	Plakalbumin, α 1-antitrypsin, antithrombin and the mechanism of inflammatory thrombosis
Cheng et al.	1994	Design and synthesis of novel cyclic RGD-containing peptides as highly potent and selective integrin. alpha. IIb. beta. 3 antagonists
JP3621412B2 (ja)	2005-02-16	フィブリン・コート・ポリマー表面
BR9814491A (pt)	2000-10-10	Bioprótese de válvula cardìaca sem stent, e, processos para substituição total de raiz de uma válvula cardìaca aórtica endógena num paciente mamìfero, e para substituição cirúrgica de uma válvula cardìaca e um segmento de tecido vascular adjacente num paciente mamìfero
HU211158A9 (en)	1995-10-30	Novel inhibitors of thrombin
DE68911178D1 (de)	1994-01-20	Klinische Entwicklungen mit Amnionzellen.
NL300009I2 (nl)	2000-12-01	Fusie-eiwitten met immuunglobulinedelen, hun bereiding en hun gebruik.
TR200102729T2 (tr)	2002-04-22	Platelet yapışmasını bloke etme amaçlı protein
WO2000024412A3 (en)	2000-08-03	Use of vegf-c or vegf-d gene or protein to prevent restenosis
Ascenzi et al.	1995	Proteinase inhibitors from the European medicinal leech Hirudo medicinalis: structural, functional and biomedical aspects
AU608602B2 (en)	1991-04-11	DNA clone of human thrombomodulin
CA2092540A1 (en)	1992-04-05	Soluble hirudin conjugates
EP0372670A3 (de)	1991-08-21	Hirudinverwandte Peptide zur Verhinderung der Plättchenaggregation
US5693098A (en)	1997-12-02	Fibrin D-domain multimer prostheses and methods for their production
ATE376001T1 (de)	2007-11-15	Kondensiertes protein, das sowohl thrombolytisch als auch gerinnungshemmend wirkt, und dessen verwendung
WO2003039491A8 (en)	2003-10-30	Novel isoforms of vascular endothelial cell growth inhibitor
NO177312B (no)	1995-05-15	Fremgangsmåte for fremstilling av hirudinderivater med forsinket virkning
NO175900B (no)	1994-09-19	Fremgangsmåte for isolering av amblyommin
Sedlarik et al.	1990	Rapid endothelialization of mieroporous vascular prostheses covered with meshed vascular tissue: a preliminary report
WO1997035886A1 (en)	1997-10-02	Surfaces which prevent or reduce complement activation
Mhic Iomhair et al.	1996	The antithrombotic effect of some EUROBIOMAT project test polymers in vivo
Iyer et al.	1996	Leading Article: Cardiovascular & Renal: Recombinant hirudin: A perspective
Badimon et al.	1990	Platelet interaction to prosthetic materials—role of von Willebrand factor in platelet interaction to PTFE
Dumanian et al.	1996	Tissue factor and its inhibition at the human microvascular anastomosis

Legal Events

Date	Code	Title	Description
2007-03-22	8364	No opposition during term of opposition